Clinical trial
Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection
NCT00806351 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2009
- Completion date
- October 31, 2011
- Enrollment
- 21 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.